Surmodics has officially launched a new division named Surmodics Services & Technologies, aimed at preserving the legacy of Biocoat. This division will manage core operations retained after the recent merger of Surmodics and Biocoat, alongside the divestiture of certain assets. Based in Horsham, Pennsylvania, Surmodics Services & Technologies is set to continue providing advanced hydrophilic and specialty coating technologies to medical device manufacturers worldwide.
Focus on Customer Collaboration and Innovation
Officials from Surmodics have stated that the new division is structured to operate as a streamlined and customer-focused organization. By fostering close collaboration with device makers throughout the entire product lifecycle, Surmodics Services & Technologies aims to provide comprehensive support. Its dedicated Project Development and Engineering team brings decades of experience, assisting clients from early-stage concepts to full commercial production.
The Horsham facility is designed to offer scalable capabilities, catering to a diverse range of clients, including start-ups, contract manufacturers, and large original equipment manufacturers. The division’s services encompass formulation development, feasibility testing, process optimization, and high-volume coating production. This positions it as a key partner for medical device innovation.
Commitment to Agility and Quality
According to Chip Hance, Chief Executive Officer of Surmodics, the launch of this new division marks a significant milestone for both the organization and its customers. He emphasized that Surmodics Services & Technologies reflects a commitment to agility, innovation, and scientific expertise. The focus will remain on maintaining strong relationships with medical device manufacturers.
Surmodics Services & Technologies is anticipated to play a vital role in the evolution of next-generation medical devices. As manufacturers increasingly seek reliable partners capable of accelerating development while adhering to stringent performance and quality standards, this new division aims to fill that gap effectively.
With its establishment, Surmodics reinforces its dedication to supporting the medical device sector, ensuring that it can respond dynamically to the changing needs of its clients. The coming months will reveal how this new venture will influence the industry landscape.
